AstraZeneca Says 'IDO' To Incyte For Imfinzi Marriage
Executive Summary
As the major immuno-oncology players seek out the best combination therapies, AstraZeneca and Incyte are starting a Phase III trial evaluating Imfinzi and the IDO inhibitor epacadostat in Stage III NSCLC.
You may also be interested in...
Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor
The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.
AZ Confident New Cancer Drugs Can Drive Return To Sales Growth
The drugs major is looking to return to sales growth in 2018 and believes that its oncology division will be the main driver as the last wave of patent expiries ebbs away.
Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal
Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.